First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Accent Therapeutics
Accent Therapeutics
Mirati Therapeutics Inc.
Baylor Research Institute
Pheon Therapeutics
Novartis
Takeda
Tempus AI
NuCana plc
Institut Bergonié
Academic and Community Cancer Research United
Eli Lilly and Company
Alaunos Therapeutics
Weill Medical College of Cornell University
Swiss Cancer Institute
Mirati Therapeutics Inc.
University of Iowa
Washington University School of Medicine